Pages that link to "Q46475895"
Jump to navigation
Jump to search
The following pages link to Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans (Q46475895):
Displaying 50 items.
- Leveraging the cortical cholinergic system to enhance attention (Q24598925) (← links)
- Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia (Q24649568) (← links)
- α7 nicotinic ACh receptors as a ligand-gated source of Ca(2+) ions: the search for a Ca(2+) optimum (Q26852967) (← links)
- Review of Pharmacological Treatment in Mood Disorders and Future Directions for Drug Development (Q26853509) (← links)
- Muscarinic agonists for the treatment of cognition in schizophrenia (Q28301970) (← links)
- Modulation of prepulse inhibition through both M(1) and M (4) muscarinic receptors in mice (Q30444290) (← links)
- Modulators in concert for cognition: modulator interactions in the prefrontal cortex (Q30493218) (← links)
- Effects of acute and sustained pain manipulations on performance in a visual-signal detection task of attention in rats (Q33733502) (← links)
- EEG machine learning for accurate detection of cholinergic intervention and Alzheimer's disease (Q33915806) (← links)
- Subregional basal forebrain atrophy in Alzheimer's disease: a multicenter study (Q33998656) (← links)
- Modes and models of forebrain cholinergic neuromodulation of cognition. (Q34355481) (← links)
- Cognitive enhancement following acute losartan in normotensive young adults (Q34628403) (← links)
- Nicotinic versus muscarinic blockade alters verbal working memory-related brain activity in older women (Q35043600) (← links)
- Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits (Q35048154) (← links)
- Plasticity of prefrontal attention circuitry: upregulated muscarinic excitability in response to decreased nicotinic signaling following deletion of α5 or β2 subunits (Q35619422) (← links)
- Towards a muscarinic hypothesis of schizophrenia. (Q36673957) (← links)
- Abnormal neurotransmitter release underlying behavioral and cognitive disorders: toward concepts of dynamic and function-specific dysregulation (Q36681956) (← links)
- The influence of scopolamine on motor control and attentional processes. (Q36881057) (← links)
- Potential therapeutic uses of mecamylamine and its stereoisomers (Q36949979) (← links)
- The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia (Q37075127) (← links)
- Synergistic effects of genetic variation in nicotinic and muscarinic receptors on visual attention but not working memory (Q37117798) (← links)
- Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme (Q37130148) (← links)
- Cholinesterase inhibitors improve both memory and complex learning in aged beagle dogs. (Q37163279) (← links)
- Classifying antipsychotic agents : need for new terminology (Q37322237) (← links)
- Pharmaceutical treatment for cognitive deficits in Alzheimer's disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps (Q37326505) (← links)
- Role of the cholinergic system in the pathology and treatment of schizophrenia. (Q37356496) (← links)
- Nicotinic acetylcholine receptors in attention circuitry: the role of layer VI neurons of prefrontal cortex. (Q37629127) (← links)
- Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: an overview of preclinical and clinical findings (Q37826637) (← links)
- Bipolar disorder: clinical perspectives and implications with cognitive dysfunction and dementia. (Q38017668) (← links)
- Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function (Q38150484) (← links)
- Pharmacokinetics and pharmacodynamics of oral mecamylamine - development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation. (Q38786004) (← links)
- Targets of polyamine dysregulation in major depression and suicide: Activity-dependent feedback, excitability, and neurotransmission. (Q38815980) (← links)
- Main Plant Extracts' Active Properties Effective on Scopolamine-Induced Memory Loss (Q39153824) (← links)
- Molecular Pathogenesis of Alzheimer's Disease: An Update (Q39355183) (← links)
- Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test (Q39510294) (← links)
- Mechanisms of Cognitive Aging in the HIV-Positive Adult (Q40070860) (← links)
- Cooperation between cholinergic and glutamatergic receptors are essential to induce BDNF-dependent long-lasting memory storage (Q42482851) (← links)
- The Ferrier Lecture 1998. The molecular biology of consciousness investigated with genetically modified mice (Q42599768) (← links)
- Sazetidine-A, a selective α4β2 nicotinic acetylcholine receptor ligand: effects on dizocilpine and scopolamine-induced attentional impairments in female Sprague–Dawley rats (Q42754120) (← links)
- Discovery of potential antipsychotic agents possessing pro-cognitive properties (Q42803307) (← links)
- Cognitive performance and cholinergic transmission: influence of muscarinic and nicotinic receptor blockade (Q42853769) (← links)
- Muscarinic antagonist effects on executive control of attention (Q43269051) (← links)
- Effects of dimethylaminoethanol pyroglutamate (DMAE p-Glu) against memory deficits induced by scopolamine: evidence from preclinical and clinical studies (Q43276176) (← links)
- Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. (Q43277955) (← links)
- The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction (Q44842565) (← links)
- Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PET. (Q46299076) (← links)
- G alpha(q)-coupled muscarinic acetylcholine receptors enhance nicotinic acetylcholine receptor signaling in Caenorhabditis elegans mating behavior. (Q47068813) (← links)
- Hippocampal chromatin-modifying enzymes are pivotal for scopolamine-induced synaptic plasticity gene expression changes and memory impairment (Q47568638) (← links)
- Scopolamine disrupts place navigation in rats and humans: a translational validation of the Hidden Goal Task in the Morris water maze and a real maze for humans (Q47868656) (← links)
- An anti-nicotinic cognitive challenge model using mecamylamine in comparison with the anti-muscarinic cognitive challenge using scopolamine. (Q48219255) (← links)